Aspect Biosystems is a privately held biotechnology company pioneering microfluidic 3D bioprinting of living, human tissue.
Aspect Biosystems combines the power of microfluidics and 3D bioprinting to create living, human tissues that will save lives and make people healthier.
Aspect Biosystems was founded in 2013 by Konrad Walus, Sam Wadsworth, Simon Beyer, and Tamer Mohamed. The company is headquartered in Vancouver, British Columbia.
Aspect Biosystems' proprietary technology has the potential to shape every aspect of human health by enabling the creation of human tissues for medical research, therapeutic discovery, and regenerative medicine.
Aspect is focused on partnering with academic institutions and biopharma companies to facilitate high-value discovery and development. The Company is also advancing internal tissue therapeutic programs for regenerative medicine, with an initial focus on metabolic diseases and musculoskeletal injuries and disorders.
Aspect Biosystems is backed by Radical Ventures, Pangaea Ventures, Pallasite Ventures, Rhino Ventures, Western Innovation (WINN) Initiative and others. The company raised $20M in a Series A financing on Jan 09, 2020. This new round brings Aspect's total funding to $23.7M to date.